Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics
Sponsor: AbbVie
Terminated
Strategic considerations
This PHASE2 trial investigates Onchocerciasis and is currently terminated or withdrawn. AbbVie leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Mar 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — Jul 2022 [monthly]
Recruiting PHASE2
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Drugs for Neglected Diseases
For direct contact, visit the study record on ClinicalTrials.gov .